key: cord-0883967-neprl6mv
authors: Hoang, Van Thuan
title: Comment to Sands et al: No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
date: 2021-02-24
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.079
sha: e1653098b773a6577c33c7ad21f63827988e6601
doc_id: 883967
cord_uid: neprl6mv

nan

started treatment after more than 3 days of admission. In addition, the duration of treatment is very short (median=5 days, rang=1-12 days). A total of 130/973 (13.4%) patients received HCQ at advanced stage of disease (required intensive care and/or ventilator support). But 40/101 (39.6%) died patients received the initial treatment at this stage. This suggests that anti-SARS-CoV-2 treatment must be introduced early.

In fact, their results showed a significantly difference of mortality between three groups of patients: 7.2% in patients received first dose while at mild severity, 21.6% and 50.0% at moderate and severe severity, respectively, p-value<0.0000 (statistical test done using OpenEpi (http://www.openepi.com/Menu/OE_Menu.htm) by Chi2 test). Gautret and colleagues [Gautret et al., 2020 , Lagier et al., 2020 showed that patients were not considered to be under treatment if they received it in <3 days.

In addition, several biomarkers which may be potential risk factors for predicting severe and fatal COVID-19 were not evaluated, such as white blood cell, lymphocyte and platelet count, d-dimer greater than 1μg/mL, high lactate dehydrogenase level and serum ferritin. [Henry et al., 2020 , Li et al., 2020 .

In their data, one BMI measurement was recorded as 2,046.3 kg/m 2 . This patient should be excluded from the study because the unrealistic nature of this value. But the authors declared that they have imputed the BMI at 29.55 kg/m 2 as the median. However, in their analysis, the BMI ranged from 13.8 to 2050 (table 1 and 3) [Sands et al., 2020] . Interestingly, in multivariable logistic regression analysis, the BMI was introduced and Odds ratio in both models was 1.00, 95%CI=[1.00-1.00]. It suggests that their final results were not reliable.

J o u r n a l P r e -p r o o f

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19